KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) EPS (Basic) (2016 - 2025)

TherapeuticsMD's EPS (Basic) history spans 16 years, with the latest figure at -$0.06 for Q4 2025.

  • For Q4 2025, EPS (Basic) fell 400.0% year-over-year to -$0.06; the TTM value through Dec 2025 reached -$0.06, up 68.42%, while the annual FY2025 figure was -$0.06, 68.42% up from the prior year.
  • EPS (Basic) reached -$0.06 in Q4 2025 per TXMD's latest filing, down from $0.01 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $12.83 in Q2 2022 to a low of -$5.7 in Q1 2022.
  • Average EPS (Basic) over 5 years is -$0.34, with a median of -$0.1 recorded in 2021.
  • Peak YoY movement for EPS (Basic): tumbled 4583.33% in 2021, then surged 5560.0% in 2022.
  • A 5-year view of EPS (Basic) shows it stood at -$0.1 in 2021, then soared by 5560.0% to $5.46 in 2022, then plummeted by 102.56% to -$0.14 in 2023, then skyrocketed by 114.29% to $0.02 in 2024, then plummeted by 400.0% to -$0.06 in 2025.
  • Per Business Quant, the three most recent readings for TXMD's EPS (Basic) are -$0.06 (Q4 2025), $0.01 (Q3 2025), and $0.05 (Q2 2025).